Prevalence, Treatment Patterns and Control Rates of Metabolic Syndrome in a Chinese Diabetic Population: China Cardiometabolic Registries 3B Study
Overview
Authors
Affiliations
Aims/introduction: To investigate the prevalence and risk factors of metabolic syndrome (MetS) in Chinese type 2 diabetes mellitus patients, and assess the effect of MetS on the treatment patterns and blood glucose, blood pressure and blood lipids goal achievements.
Materials And Methods: Data from 25,454 type 2 diabetes mellitus patients including demographic data, anthropometric measurements, treatment patterns, and blood glucose and lipid profiles were retrospectively analyzed.
Results: Using modified Adult Treatment Panel III MetS criteria, the prevalence of MetS was 57.4% in type 2 diabetes mellitus patients. Multivariable logistic regression analysis showed that type 2 diabetes mellitus patients, who also fulfilled the criteria for MetS, tended to be women, living in the northeast, with a diabetes duration ≥5 years and leading a sedentary lifestyle. Most MetS (53.4%) and non-MetS (57%) diabetes patients received oral hypoglycemic drugs. Insulin or insulin combination therapies were more applied in MetS (37.5%) than in non-MetS (33.1%) diabetes patients, and the percentages of MetS diabetes patients receiving antihypertensive and lipid-modulating drugs were 52.9% and 28.2% vs 38.3% and 19.3% of the non-MetS diabetes patients. Just 37.5%, 15.6% and 32.9% of the MetS diabetes patients vs 54.6%, 45.6% and 40.4% of the non-MetS diabetes patients achieved the individual target goals for control of blood glucose (glycosylated hemoglobin <7%), blood pressure (systolic blood pressure <130 mmHg, diastolic blood pressure <80 mmHg) and blood lipids (total cholesterol <4.5 mmol/L), whereas just 2.1% achieved all three target goals.
Conclusions: MetS with a high prevalence in Chinese type 2 diabetes mellitus patients is associated with poor blood glucose, blood pressure and blood lipids control rate.
Li Z, Feng L, Long J, Xiong Y, Li T, Jiang B Vaccines (Basel). 2024; 12(8).
PMID: 39204024 PMC: 11360589. DOI: 10.3390/vaccines12080898.
Ji Q, Chai S, Zhang R, Li J, Zheng Y, Rajpathak S Front Endocrinol (Lausanne). 2024; 15:1362433.
PMID: 38919489 PMC: 11196810. DOI: 10.3389/fendo.2024.1362433.
Gong S, Gan S, Zhang Y, Zhou H, Zhou Q Front Endocrinol (Lausanne). 2023; 14:1248614.
PMID: 37854188 PMC: 10579940. DOI: 10.3389/fendo.2023.1248614.
Metabolic Syndrome in Patients With Diabetes Mellitus.
Essafi M, Bouabdellaoui L, Aynaou H, Salhi H, El Ouahabi H Cureus. 2022; 14(4):e24469.
PMID: 35637809 PMC: 9132124. DOI: 10.7759/cureus.24469.
Huang X, Zhan H, Yang J, Peng L, Piao S, Wang L Evid Based Complement Alternat Med. 2021; 2021:6264414.
PMID: 34707672 PMC: 8545570. DOI: 10.1155/2021/6264414.